<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="case-report" dtd-version="1.0" xml:lang="HR" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-142-2</article-id>
<article-id pub-id-type="doi">10.26800/LV-142-1-2-1</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Case report</subject></subj-group>
</article-categories>
<title-group>
<article-title>Euglikemijska dijabeti&#x010D;ka ketoacidoza inducirana empagliflozinom, inhibitorom kotransportera natrija i glukoze 2, nakon resekcijskog zahvata na plu&#x0107;ima u bolesnice s tipom 2 &#x0161;e&#x0107;erne bolesti</article-title>
<trans-title-group xml:lang="en">
<trans-title>Euglycemic diabetic ketoacidosis induced by empagliflozin, sodium-glucose cotransporter-2 inhibitor, in patient with diabetes mellitus type 2 after thoracic surgery</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Maga&#x0161; Vadlja</surname><given-names>Jelena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x0160;pi&#x010D;ek-Macan</surname><given-names>Jasna</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Katan&#x010D;i&#x0107;</surname><given-names>Jadranka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mili&#x0161;i&#x0107; Ja&#x0161;arevi&#x0107;</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karad&#x017E;a</surname><given-names>Vjekoslav</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Copi&#x0107;</surname><given-names>Marija</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Odjel za anesteziologiju, reanimatologiju i intenzivno lije&#x010D;enje, Klinika za torakalnu kirurgiju, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
</contrib-group>
<author-notes><corresp id="cor1">Adresa za dopisivanje: Dr. Jelena Maga&#x0161; Vadlja, Klinika za torakalnu kirurgiju, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu, KBC Zagreb, Jordanovac 104, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="jmagas78@yahoo.com">jmagas78@yahoo.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>02</month><year>2020</year></pub-date>
<volume>142</volume>
<issue>1-2</issue>
<fpage>2</fpage>
<lpage>5</lpage>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Inhibitori kotransportera natrija i glukoze 2 (engl. <italic>Sodium-glucose cotransporter-2 inhibitors</italic> &#x2013; SGLT2i) noviji su oralni antidijabetici koji mogu uzrokovati euglikemijsku dijabeti&#x010D;ku ketoacidozu (eDKA), i to &#x010D;e&#x0161;&#x0107;e kod bolesnika sa &#x0161;e&#x0107;ernom bolesti tipa 1, a rijetko u onih s tipom 2 &#x0161;e&#x0107;erne bolesti. Glavna karakteristika eDKA-a jest gotovo normalna razina glukoze u krvi (GUK) uz metaboli&#x010D;ku ketoacidozu. U na&#x0161;em prikazu rije&#x010D; je o 42-godi&#x0161;njoj bolesnici u koje su se u ranome postoperativnom periodu, uz gotovo normalne vrijednosti GUK-a, razvili metaboli&#x010D;ka acidoza, povra&#x0107;anje i pospanost. Sumnju da se radi o dijabeti&#x010D;koj ketoacidozi potvrdio je, uz ostalo, pozitivan nalaz ketona u urinu. Na temelju klini&#x010D;ke slike, nalaza plinskih analiza arterijske krvi i laboratorijskih nalaza krvi i urina postavila se dijagnoza eDKA-a, nastalog kao posljedica SGLT2i-ja. Bolesnica je lije&#x010D;ena inzulinom, kristaloidnim otopinama i elektrolitima. Tre&#x0107;ega postoperativnog dana lije&#x010D;enja otpu&#x0161;tena je s Odjela anestezije i intenzivnog lije&#x010D;enja na Kirur&#x0161;ki odjel, uz prethodni pregled endokrinologa. Rutinska perioperativna provjera plinskih analiza arterijske krvi pomogla nam je pri detekciji bolesti i lije&#x010D;enju bolesnice. Ovaj prikaz upu&#x0107;uje na va&#x017E;nost ranoga preoperativnog probira pacijenata na SGLT2i, mogu&#x0107;i nastanak eDKA-a, va&#x017E;nost preoperativne pripreme i potrebe za lije&#x010D;enjem.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Sodium-glucose cotransporter-2 inhibitors(SGLT2i) medications are a class of newer antihyperglycemic agents that can induce euglycemic diabetic ketoacidosis (eDKA), usually in patients with diabetes mellitus type 1,but very rarely in patients with diabetes mellitus type 2. The main characteristic of eDKA is that blood glucose level(BGL) is nearly normal. We present a case report of a 42-year-old patient who was scheduled for elective thoracic surgery in which in the early postoperative period she developed metabolic acidosis with nausea and vomiting. Ketones in urine were positive and it was recognized as eDKA induced by SGLT2i. She was treated with intravenous insulin, fluids and electrolytes. She was dismissed from ICU on the third day to surgery department after endocrinologist&#x00B4;s review. Arterial blood gas samples are a part of our routine preoperative and postoperative procedures that helped us in the detection and treatment of this patient. This case report points out the importance of early recognition of patients on SGLT2i, appropriate preoperative assessment, and eventually the need for treatment.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori DIJABETI&#x010C;KA KETOACIDOZA &#x2013; dijagnoza, kemijski izazvana, lije&#x010D;enje</kwd><kwd>&#x0160;E&#x0106;ERNA BOLEST TIPA 2 &#x2013; farmakoterapija</kwd><kwd>INHIBITORI SUPRIJENOSNIKA NATRIJA I GLUKOZE 2 &#x2013; nuspojave, farmakologija</kwd><kwd>ANTIDIJABETICI &#x2013; nuspojave, farmakologija</kwd><kwd>POSLIJEOPERACIJSKE KOMPLIKACIJE &#x2013; dijagnoza, kemijski izazvane, lije&#x010D;enje</kwd><kwd>PLU&#x0106;NI TUMORI &#x2013; kirurgija</kwd><kwd>PLINSKA ANALIZA KRVI</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>DIABETIC KETOACIDOSIS &#x2013; chemically induced, diagnosis, therapy</kwd><kwd>DIABETES MELLITUS, TYPE 2 &#x2013; drug therapy</kwd><kwd>SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS &#x2013; adverse effects, pharmacology</kwd><kwd>HYPOGLYCEMIC AGENTS &#x2013; adverse effects, pharmacology</kwd><kwd>POSTOPERATIVE COMPLICATIONS &#x2013; chemically induced, diagnosis, therapy</kwd><kwd>LUNG NEOPLASMS &#x2013; surgery</kwd><kwd>BLOOD GAS ANALYSIS</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Inhibitori kotransportera natrija i glukoze 2 noviji su oralni antidijabetici koji se rabe za lije&#x010D;enje tipa 2 &#x0161;e&#x0107;erne bolesti. Pove&#x0107;ana primjena empagliflozina (SGLT2i) posljedica je dobrih rezultata studije EMPA-REG OUTCOME. Studija je pokazala da primjena SGLT2i-ja smanjuje postotak HbA<sub>1c</sub>, potrebu za inzulinom i tjelesnu te&#x017E;inu, skra&#x0107;uje hospitalizacije zbog sr&#x010D;anog zatajivanja te sni&#x017E;ava stopu smrtnosti od svih uzroka. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) SGLT2i djeluje na kotransporter epitelnih stanica proksimalnih kanali&#x0107;a bubrega i sprje&#x010D;ava reapsorpciju Na i glukoze. Pritom dolazi do glukozurije, sni&#x017E;enja vrijednosti GUK-a i smanjenog izlu&#x010D;ivanja inzulina. Sni&#x017E;enje razine natrija dovodi do gubitka teku&#x0107;ine i pada tlaka. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) SGLT2i mo&#x017E;e uzrokovati eDKA u bolesnika s tipom 1 &#x0161;e&#x0107;erne bolesti i u onih sa &#x0161;e&#x0107;ernom bolesti tipa 2, (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) pri prolongiranom gladovanju, (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) kod velikih kirur&#x0161;kih operacija (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>), u alkoholi&#x010D;ara, (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) pri dehidraciji (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) i kod dijete s malenim udjelom ugljikohidrata. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) U ovom radu prikazujemo bolesnicu koja je nakon resekcijskog zahvata na plu&#x0107;ima dobila eDKA.</p>
<sec sec-type="other1">
<title>Prikaz bolesnice</title>
<p>U 42-godi&#x0161;nje bolesnice A. K., fizikalnog statusa 3 prema klasifikaciji ASA-e (engl. <italic>American Society of Anesthesiologists Classification</italic>), planiran je elektivni resekcijski zahvat tumora u lijevome gornjem re&#x017E;nju plu&#x0107;a. Tijekom anesteziolo&#x0161;kog pregleda u anamnezi su utvr&#x0111;eni: tip 2 &#x0161;e&#x0107;erne bolesti, arterijska hipertenzija, stanje poslije desne mastektomije nakon koje su provedeni kemoterapija i zra&#x010D;enje. Kao terapiju uzimala je empagliflozin/metformin, alogliptin benzoat/metformin hidroklorid i perindopril. Rutinska preoperativna analiza plinske arterijske krvi i laboratorijski nalazi bubre&#x017E;ne funkcije bili su u granicama normale. Vrijednost GUK-a iznosila je 12,3 mmol/L. U urinu su bili pozitivni glukoza +4 i ketoni +1. U zaklju&#x010D;ku anesteziolo&#x0161;kog pregleda preporu&#x010D;eno je isklju&#x010D;iti oralne antidijabetike 24 sata prije operacije, &#x0161;to nije u&#x010D;injeno. Preoperativne vrijednosti GUK-a na Kirur&#x0161;kom odjelu iznosile su 11,2 &#x2013; 7 mmol/L. Bolesnica je bila prva na redu za operaciju. Kirur&#x0161;ki zahvat trajao je 2 sata i 15 minuta. Intraoperativno je dobila 1000 mL izotoni&#x010D;ne otopine natrijeva klorida bez intraoperativnog krvarenja. Pra&#x0107;enje (monitoring) je bilo pro&#x0161;ireno invazivnim mjerenjem arterijskoga krvnog tlaka. Tijek anestezije i operacije pro&#x0161;ao je bez incidenata. U&#x010D;injene su lijeva minitorakotomija i ekstirpacija tumora lijevoga gornjeg re&#x017E;nja plu&#x0107;a. Bolesnica je za vrijeme anestezije dobila 1,1 mcg/kg sufentanila (ukupno 80 mcg). Nakon dolaska u jedinicu intenzivnog lije&#x010D;enja (JIL) bila je budna, ekstubirana, hemodinamski stabilna i respiratorno suficijentna. U JIL-u je nastavljena analgezija sufentanilom u dozi od 4 mcg/sat, ketoprofenom 2 &#x00D7; 100 mg iv. i metamizol natrijem 3 &#x00D7; 1,5 g iv. Poslije dolaska u JIL pacijenti&#x010D;ina procjena ja&#x010D;ine boli na vizualno-analognoj skali (engl. <italic>Visual analogue scale</italic> &#x2013; VAS) iznosila je 3 &#x2013; 4, a u daljnjem tijeku lije&#x010D;enja 1 &#x2013; 2. U prvim postoperativnim analizama arterijske krvi uo&#x010D;ena je acidoza uz uredne vrijednosti pCO<sub>2</sub> (<xref ref-type="table" rid="t1">Table 1</xref>). Vrijednosti GUK-a bile su gotovo normalne (<xref ref-type="table" rid="t1">Table 1</xref>). Primije&#x0107;eni su niska razina bikarbonata i manjak baza (<xref ref-type="table" rid="t1">Table 1</xref>). U po&#x010D;etku su ovi nalazi shva&#x0107;eni kao deplecija volumena. Bolesnici je ordinirano 1000 mL balansirane kristaloidne otopine tijekom 6 sati. Nave&#x010D;er je obilno povratila u dva navrata. Vrijednosti GUK-a iznosile su 9,6 &#x2013; 7,0 &#x2013; 8,2 mmol/L. Metoda testne tra&#x010D;ice pokazala je razinu ketona u urinu +3. Laboratorijski nalazi, preoperativno neizostavljen SGLT2i i klini&#x010D;ka slika potvrdili su inhibitore kotransportera natrija i glukoze 2 (SGLT2i) kao uzrok eDKA-a. Zapo&#x010D;eto je lije&#x010D;enje izotoni&#x010D;nom otopinom natrijeva klorida, 5%-tnom otopinom glukoze, intravenskim brzodjeluju&#x0107;im humanim inzulinom i nadoknadom kalijeva klorida. Bolesnica je dobila 1600 mL izotoni&#x010D;ne otopine natrijeva klorida brzinom od 300 mL/sat. Unato&#x010D; urednim vrijednostima kalij je nadokna&#x0111;en s ukupno 20 mmol kalijeva klorida (<xref ref-type="table" rid="t1">Table 1</xref>). Kada je vrijednost GUK-a bila 8,9 mmol/L, ordiniran je kontinuirani intravenski brzodjeluju&#x0107;i humani inzulin brzinom od 7 i. j./sat. Nakon &#x0161;to se vrijednost GUK-a snizila na 6,3 mmol/L, brzina inzulina smanjena je na 4 i. j./sat i ordinirano je 500 mL 5%-tne glukoze. U daljnjem tijeku pratili su se GUK i elektroliti iz plinskih analiza arterijske krvi (<xref ref-type="table" rid="t1">Table 1</xref>). Bolesnici je uveden urinarni kateter, mjerili su se satna diureza i ukupan promet teku&#x0107;ina. Drena&#x017E;a na torakalni dren nije bila znatna. U mentalnom statusu primije&#x0107;ene su pospanost i usporenost. Izmjerena osmolalnost krvi iznosila je 270 mOsmol/kg (referentne vrijednosti 275 &#x2013; 295 mOsmol/kg). Sljede&#x0107;eg dana bolesnici je nastavljeno kontinuirano davanje intravenskoga humanog inzulina uz 5%-tnu glukozu do ve&#x010D;eri, da bi se nave&#x010D;er isklju&#x010D;ilo na vrijednosti GUK-a od 9,0 mmol/L. Dalje je mogla adekvatno uzimati vodu na usta bez povra&#x0107;anja. Zahvaljuju&#x0107;i poduzetim mjerama lije&#x010D;enja, manjak baza smanjio se s -13,2 mmol/L na -8 mmol/L. U laboratorijskim nalazima uo&#x010D;en je blagi pad fosfata koji se nadoknadio. Drugoga postoperativnog dana konzultiran je endokrinolog dijabetolog koji je postavio dijagnozu dijabeti&#x010D;ke ketoacidoze koja bi, teoretski, mogla biti posljedica SG2LTi-ja. Tada je nalaz ketona iz prsta bio 1,3 mmol/L. Endokrinolog je preporu&#x010D;io bolusnu inzulinsku terapiju inzulina asparta u dozi od 4 do 6 i. j. sc. 3 &#x00D7; na dan prije obroka i bazalni humani inzulin u dozi od 10 i. j. sc. nave&#x010D;er. Tre&#x0107;ega postoperativnog dana bolesnica je otpu&#x0161;tena na Kirur&#x0161;ki odjel. Plinske analize arterijske krvi pri otpustu iz JIL-a pokazale su: pH 7,30; pCO<sub>2</sub> 34 mmHg; pO<sub>2</sub> 112 mmHg; Lac 0,4 mmol/L; HCO<sub>3</sub> 16,7 mmol/L; BE -9,7mmol/L; SO<sub>2</sub> 98%. Na Kirur&#x0161;kom odjelu bolesnica je boravila 4 dana. Kontrola endokrinologa obavljena je prije otpusta iz bolnice. Endokrinolog je isklju&#x010D;io empagliflozin/metformin iz daljnje terapije, a ostavio alogliptin benzoat/metformin hidroklorid. Inzulin aspart i bazalni humani inzulin isklju&#x010D;eni su. Bolesnici je preporu&#x010D;ena kontrola endokrinologa uz pra&#x0107;enje HbA<sub>1C</sub>, lipidograma, jetrenih enzima i kreatinina.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Arterial blood gases in patient on zero postoperative day</title>
</caption>
<table frame="hsides" rules="groups">
<col width="23.1%"/>
<col width="9.6%"/>
<col width="9.62%"/>
<col width="9.62%"/>
<col width="9.6%"/>
<col width="9.62%"/>
<col width="9.62%"/>
<col width="9.6%"/>
<col width="9.62%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Vrijeme/Time</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">11:07</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">20:03</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">23:35</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">00:42</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">01:43</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">02:52</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">03:43</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">04:44</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">pH</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,18</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,19</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,13</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,17</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,21</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,22</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,21</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">7,24</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">pCO<sub>2</sub>*</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">43</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">30</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">30</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">29</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">32</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">32</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">32</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">32</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">pO<sub>2</sub>*</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">246</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">149</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">140</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">139</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">140</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">140</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">140</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">115</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Na**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">135</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">135</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">135</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">134</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">134</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">134</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">133</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">133</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">K**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3,9</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3,9</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3,9</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4,0</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">4,2</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">GUK**<break/>BGL**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12,0</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8,2</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8,9</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,9</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,2</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,2</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">6,3</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Laktati**/Lactic acid**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,7</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,5</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,4</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0,5</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">0,4</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">HCO<sub>3</sub>**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">15,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">11,5</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">10</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">10,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">14,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">13,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">12,8</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">13,7</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">BE**</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-12,4</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-16,7</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-19,2</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-17,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-15,3</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-14,6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">-15,1</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">-13,7</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">SO<sub>2</sub>***</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">100</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">99</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">98</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">98</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">99</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">99</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">99</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">98</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>* mmHg; ** mmol/L; *** %</p>
</table-wrap-foot></table-wrap>
</sec>
<sec sec-type="other2">
<title>Rasprava</title>
<p>Dijabeti&#x010D;ka ketoacidoza naj&#x010D;e&#x0161;&#x0107;e je hiperglikemijska. Euglikemijska dijabeti&#x010D;ka ketoacidoza te&#x0161;ko se prepoznaje zbog gotovo normalne vrijednosti GUK-a. Vrijednosti GUK-a u hiperglikemijskoj ketoacidozi vi&#x0161;e su od 26,3 &#x00B1; 14,8 mmol/L, (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) dok je pri euglikemijskoj ketoacidozi GUK &lt; 14,0 mmol/L. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) U tipi&#x010D;noj ketoacidozi pH je 7,2 &#x00B1; 0,02, bikarbonati su 12,1 &#x00B1; 6,6 mmol/L, BE negativni 16 &#x00B1; 8 mmol/L. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Dijabeti&#x010D;ka ketoacidoza mo&#x017E;e biti blaga, srednja i te&#x0161;ka (<xref ref-type="table" rid="t2">Table 2</xref>).</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Level of severity of diabetic ketoacidosis taking into account arterial ph, serum bicarbonate, serum ketones, anion gap, alteration in sensoria or mental obtundation</title>
</caption>
<table frame="hsides" rules="groups">
<col width="24.41%"/>
<col width="20.73%"/>
<col width="31.7%"/>
<col width="23.16%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Razina DKA-a/Level of severity of DKA</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Blagi/Mild</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Srednji/Moderate</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Te&#x0161;ki/Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Arterijski pH/Arterial pH</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,25 &#x2013; 7,30</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,00 &#x2013; 7,24</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&lt; 7,00</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Serumski bikarbonati*/Serum bicarbonate*</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">15 &#x2013; 18</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">10 &#x2013; &lt; 15</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&lt; 10</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Serumski ketoni*/Serum ketones*</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">3 &#x2013; 4</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4 &#x2013; 8</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&gt; 8</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Anionski procjep*/Anion gap*</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&gt; 10</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">&gt; 12</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&gt; 12</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">Promjena mentalnog statusa/Alteration in sensoria or mental obtundation</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">budnost<break/>Alert</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">budnost/pospanost<break/>Alert/drowsy</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">stupor/koma<break/>Stupor/coma</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>* mmol/L</p>
</table-wrap-foot></table-wrap>
<p>SGLT2i djeluje na kotransporter epitelnih stanica proksimalnih kanali&#x0107;a bubrega i sprje&#x010D;ava reapsorpciju Na i glukoze. Pritom dolazi do glukozurije, sni&#x017E;enja razine vrijednosti GUK-a koje uzrokuje smanjeno izlu&#x010D;ivanje inzulina. To dovodi do pove&#x0107;anog izlu&#x010D;ivanja glukagona koji pokre&#x0107;e glukoneogenezu i glikogenolizu. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Smanjeno izlu&#x010D;ivanja inzulina dovodi do lipolize i pove&#x0107;ane sinteze slobodnih masnih kiselina koje ulaze u jetru i beta-oksidacijom pretvaraju se u ketonska tijela. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) SGLT2i tako&#x0111;er izravno djeluje na alfa-stanice gu&#x0161;tera&#x010D;e i uzrokuje porast glukagona (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) koji djeluje na porast ketonskih tijela. Djelovanjem SGLT2i-ja smanjuje se reapsorpcija Na, ali se pove&#x0107;ava reapsorpcija ketona, &#x0161;to sve pridonosi daljnjoj ketoacidozi. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Zbog smanjene reapsorpcije Na dolazi do volumne deplecije, &#x0161;to mo&#x017E;e uzrokovati hemodinamsku nestabilnost u perioperativnom razdoblju.</p>
<p>Simptomi dijabeti&#x010D;ke ketoacidoze jesu: mu&#x010D;nina, povra&#x0107;anje, promjena mentalnog statusa, &#x017E;e&#x0111;a, dispneja, tahipneja, Kussmaulovo disanje, hipovolemija. Klini&#x010D;ka slika dijabeti&#x010D;ke ketoacidoze mo&#x017E;e se preklapati s postoperativnom mu&#x010D;ninom i povra&#x0107;anjem koji nastaju kao posljedica vi&#x0161;ih intraoperativnih i postoperativnih doza opioida. Uvidom u analize plinske arterijske krvi zaklju&#x010D;ili smo da se radi o acidozi. Bolesnica je bila respiratorno suficijentna. Parcijalni tlakovi kisika i ugljikova dioksida bili su u granicama normale, &#x0161;to je isklju&#x010D;ilo respiratornu komponentu uzroka acidoze. Anionski procjep bio je ve&#x0107;i od 12 mmol/L, uz manjak baza i bikarbonata, &#x0161;to nas je uputilo prema metaboli&#x010D;kom uzroku zbivanja. Metaboli&#x010D;ka ketoacidoza mo&#x017E;e biti posljedica vi&#x0161;e uzroka kao &#x0161;to su gladovanje, &#x0161;e&#x0107;erna bolest, metanol, uremija, propilen glikol/paracetamol, infekcija/izonijazid, lakti&#x010D;na acidoza, etilen glikol, salicilati, renalna tubularna acidoza i hiperkloremi&#x010D;na metaboli&#x010D;ka acidoza kao posljedica obilne volumne nadoknade izotoni&#x010D;nom otopinom natrijeva klorida. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) Bolesnica je u terapiji imala metformin koji bi mogao uzrokovati metaboli&#x010D;ku laktacidozu, ali vrijednost laktata bila je normalna (<xref ref-type="table" rid="t1">Table 1</xref>). Bubre&#x017E;na funkcija bila je u granicama normale. Bolesnica je intraoperativno dobila optimalnu koli&#x010D;inu izotoni&#x010D;ne otopine natrijeva klorida. Daljnji tijek lije&#x010D;enja nastavljen je balansiranim kristaloidnim otopinama. Veliki kirur&#x0161;ki zahvat uzrokuje neuroendokrini stresni odgovor koji sni&#x017E;ava razinu inzulina, pove&#x0107;ava perifernu inzulinsku rezistenciju i glukoneogenezu, &#x0161;to pogoduje nastanku eDKA-a kod operiranih bolesnika na SGLT2i-ju. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Svi na&#x0161;i bolesnici dobivaju obilnu intraoperativnu analgeziju, a zatim i postoperativnu. Procjena boli na VAS-u u na&#x0161;e je bolesnice u po&#x010D;etku bila 3 &#x2013; 4, a poslije 1 &#x2013; 2, &#x0161;to govori u prilog optimalnoj perioperativnoj analgeziji. Zahvaljuju&#x0107;i na&#x0161;im prija&#x0161;njim saznanjima da SGLT2i mo&#x017E;e izazvati eDKA i vidjev&#x0161;i metaboli&#x010D;ku acidozu u rutinskim postoperativnim kontrolama plinskih analiza arterijske krvi, rano smo posumnjali da se radi o eDKA-u uzrokovanom SGLT2i-jem. Literatura &#x010D;esto navodi da se eDKA uzrokovan SGLT2i-jem kasno otkriva zbog gotovo normalne razine GUK-a. Mogu&#x0107;i uzrok pojave eDKA-a kod na&#x0161;e bolesnice jest izostavljeni prekid davanja SGLT2i-ja barem 24 sata prije operacije. Stajali&#x0161;ta vezana za vrijeme preoperativnog ukidanja SGLT2i-ja nejasna su i preporuke su od 24 sata do 48 sati. Poluvrijeme izlu&#x010D;ivanja SGLT2i-ja jest 11 &#x2013; 13 sati te se u literaturi tako&#x0111;er preporu&#x010D;uju bar 3 &#x2013; 5 poluvremena od prestanka uzimanja lijeka prije operacije, &#x0161;to bi bila 2 &#x2013; 3 dana. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Pove&#x0107;ano izlu&#x010D;ivanje Na dovodi do sni&#x017E;enja koncentracije plazmatskog Na i hipovolemije. Osmolalnost plazme na&#x0161;e bolesnice bila je ne&#x0161;to ni&#x017E;a od referentnih vrijednosti, 270 mOsmol/kg, a i razina Na kretala se od 133 do 135 mmol/L (referentne vrijednosti 137 &#x2013; 146 mmol/L). Volumna nadoknada kristaloidnim otopinama dio je lije&#x010D;enja eDKA-a uzrokovanog SGLT2i-jem. Uzimaju&#x0107;i u obzir analize plinske arterijske krvi (<xref ref-type="table" rid="t1">tablica 1</xref>.) i razinu acidoze (<xref ref-type="table" rid="t2">tablica 2</xref>.), na&#x0161;a bolesnica imala je srednje te&#x0161;ku metaboli&#x010D;ku ketoacidozu s pospano&#x0161;&#x0107;u koja se brzo razrije&#x0161;ila zahvaljuju&#x0107;i na&#x0161;emu ranom prepoznavanju i lije&#x010D;enju novonastalog poreme&#x0107;aja pa nije trebala nadoknadu bikarbonata.</p>
<p>Kod preoperativne pripreme bolesnika koji u terapiji imaju SGLT2i treba imati visok stupanj sumnje na mogu&#x0107;nost razvoja eDKA-a. Preoperativna priprema takvog bolesnika uklju&#x010D;ila bi: ukidanje SGLT2i-ja najmanje 24 sata do 48 sati prije operacije, izbjegavanje gladovanja i dehidracije, mjerenje profila GUK-a i testiranje urina na ketone tra&#x010D;icom, volumnu nadoknadu kristaloidnim otopinama, uvo&#x0111;enje inzulina u bolusima iv. ili sc. prema profilu GUK-a. Pozitivni ketoni u urinu mogu poja&#x010D;ati sumnju da se kod takvih bolesnika mo&#x017E;e razviti eDKA. Kod velikih kirur&#x0161;kih operacija analiza plinske arterijske krvi i GUK-a mogla bi pomo&#x0107;i pri detekciji eDKA-a. Postavljanjem sumnje na intraoperativni razvoj eDKA-a bolesnika treba lije&#x010D;iti inzulinom, nadoknadom kristaloidnih otopina, nadoknadom elektrolita i otopinama glukoze. Pri te&#x0161;koj acidozi treba dati i bikarbonate. Dobra premedikacija i dobra analgezija mogu ubla&#x017E;iti neuroendokrini stresni odgovor na bol i operaciju. Tako&#x0111;er, valja biti svjestan da se u bolesnika koji su u JIL-u mo&#x017E;e razviti eDKA u ranom ili kasnome postoperativnom periodu. Bolesnicima treba pratiti GUK, testirati urin na ketone tra&#x010D;icom i pratiti analize plinske arterijske krvi. Inzulin, volumna nadoknada kristaloidima i nadoknada elektrolita osnova su lije&#x010D;enja eDKA-a u JIL-u.</p>
</sec>
<sec sec-type="other3">
<title>Zaklju&#x010D;ak</title>
<p>Euglikemijska dijabeti&#x010D;ka ketoacidoza posljedica je SGLT2i-ja. Cilj prikaza poput ovoga na&#x0161;e bolesnice jest pove&#x0107;anje svjesnosti o pojavi eDKA-a zbog primjene SGLT2i-ja uz gotovo normalnu razinu GUK-a. Na&#x0161;u prednost pri otkrivanju eDKA-a omogu&#x0107;ila je rutinska analiza plinske arterijske krvi u sklopu postoperativnog pra&#x0107;enja i lije&#x010D;enja bolesnik&#x00E2;, &#x0161;to nam je pomoglo u detekciji i lije&#x010D;enju na&#x0161;e bolesnice.</p>
</sec>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><etal/><collab>EMPA-REG OUTCOME Investigators</collab></person-group>. <article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.</article-title> <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>22</issue>):<fpage>2117</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id><pub-id pub-id-type="pmid">26378978</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x2019;Emden</surname><given-names>M</given-names></name><name><surname>Amerena</surname><given-names>J</given-names></name><name><surname>Deed</surname><given-names>G</given-names></name><name><surname>Pollock</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group>. <article-title>SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus.</article-title> <source>Diabetes Res Clin Pract</source>. <year>2018</year>;<volume>136</volume>:<fpage>23</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2017.11.023</pub-id><pub-id pub-id-type="pmid">29196150</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banakh</surname><given-names>I</given-names></name><name><surname>Kung</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Matthiesson</surname><given-names>K</given-names></name><name><surname>Tiruvoipati</surname><given-names>R</given-names></name></person-group>. <article-title>Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes.</article-title> <source>Clin Case Rep</source>. <year>2019</year>;<volume>7</volume>:<fpage>1087</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1002/ccr3.2147</pub-id><pub-id pub-id-type="pmid">31110751</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>KR</given-names></name><name><surname>Schumacher</surname><given-names>CA</given-names></name><name><surname>Harpe</surname><given-names>SE</given-names></name></person-group>. <article-title>SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature.</article-title> <source>Pharmacotherapy</source>. <year>2017</year>;<volume>37</volume>(<issue>2</issue>):<fpage>187</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/phar.1881</pub-id><pub-id pub-id-type="pmid">27931088</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>Buschur</surname><given-names>EO</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Cohan</surname><given-names>P</given-names></name><name><surname>Diner</surname><given-names>JC</given-names></name><name><surname>Hirsch</surname><given-names>IB</given-names></name></person-group>. <article-title>Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium&#x2010;glucose cotransporter 2 inhibition.</article-title> <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>(<issue>9</issue>):<fpage>1687</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.2337/dc15-0843</pub-id><pub-id pub-id-type="pmid">26078479</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>RM</given-names></name><name><surname>Berard</surname><given-names>LD</given-names></name><name><surname>Cheng</surname><given-names>AYY</given-names></name><etal/></person-group> <article-title>SGLT2 inhibitor&#x2010;associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis.</article-title> <source>Clin Ther</source>. <year>2016</year>;<volume>38</volume>(<issue>12</issue>):<fpage>2654</fpage>&#x2013;<lpage>64.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2016.11.002</pub-id><pub-id pub-id-type="pmid">28003053</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>B</given-names></name><name><surname>Pilcher</surname><given-names>D</given-names></name><name><surname>Prins</surname><given-names>J</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>TJ</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name></person-group>. <article-title>Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New Zealand.</article-title> <source>Crit Care</source>. <year>2015</year>;<volume>19</volume>:<fpage>451</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-015-1171-7</pub-id><pub-id pub-id-type="pmid">26715333</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>W</given-names></name><name><surname>Sakaguchi</surname><given-names>K</given-names></name></person-group>. <article-title>Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.</article-title> <source>J Diabetes Investig</source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>135</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/jdi.12401</pub-id><pub-id pub-id-type="pmid">27042263</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kibbey</surname><given-names>RG</given-names></name></person-group>. <article-title>SGLT-2 inhibition and glucagon: cause for alarm?</article-title> <source>Trends Endocrinol Metab</source>. <year>2015</year>;<volume>26</volume>(<issue>7</issue>):<fpage>337</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2015.05.011</pub-id><pub-id pub-id-type="pmid">26059706</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniele</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Solis-Herrera</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes.</article-title> <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>(<issue>11</issue>):<fpage>2036</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2337/dc15-2688</pub-id><pub-id pub-id-type="pmid">27561923</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>D</given-names></name><name><surname>Pongracz</surname><given-names>B</given-names></name><name><surname>Titus</surname><given-names>B</given-names></name></person-group>. <article-title>Euglycemic ketoacidosis in a postoperative deformity correction spine surgery patient: a case report.</article-title> <source>J Emerg Crit Care Med</source>. <year>2018</year>;<volume>2</volume>:<fpage>83</fpage>. <pub-id pub-id-type="doi">10.21037/jeccm.2018.10.09</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>M-K</given-names></name><name><surname>Chen</surname><given-names>G-L</given-names></name><name><surname>Chuang</surname><given-names>T-J</given-names></name></person-group>. <article-title>Dapagliflozin-induced postoperative euglycemic diabetic ketoacidosis: Two cases.</article-title> <source>J Intern Med Taiwan</source>. <year>2019</year>;<volume>30</volume>:<fpage>47</fpage>&#x2013;<lpage>50</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>
